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ABSTRACT
Introduction: Maternal smoking during pregnancy is
associated with adverse perinatal and postnatal health
outcomes. The efficacy of nicotine replacement
therapies in helping pregnant smokers to quit is not
clearly demonstrated; therefore new interventions
should be proposed and assessed. Financial incentives
rewarding abstinence from tobacco smoking is one of
the promising
options.
Objective: To assess the efficacy of financial
incentives on smoking abstinence among French
pregnant smokers.
Methods and analysis: Participants: pregnant
smokers aged ≥18 years, smoking at least five
manufactured or three roll-your-own cigarettes per day,
and pregnant for <18 weeks of amenorrhoea (WA).
Setting: participants will be recruited, included and
followed-up at monthly face-to-face visits in 16
maternity wards in France. Interventions: participants
will be randomised to a control or an intervention
group. After a predefined quit date, participants in the
control group will receive €20 vouchers at the
completion of each visit but no financial incentive for
smoking abstinence. Participants in the intervention
group will be rewarded for their abstinence by
vouchers on top of the €20 show-up fee. The amount
of reward for abstinence will increase as a function of
duration of abstinence to stimulate longer periods of
abstinence. Main outcome measure: complete
abstinence from quit date to the last predelivery
visit. Secondary outcome measures: point
prevalence abstinence, time to relapse to smoking,
birth weight, fetal growth restriction, preterm birth.
Main data analysis: outcomes will be analysed on an
intention-to-treat (ITT) basis. The ITT population is
defined as all randomised smoking pregnant
women.
Ethics and dissemination: The research protocol
was approved by the ethics committee (Comité de
Protection des Personnes, CPP) of the Pitié-Salpêtrière
Hospital on 15 May 2015, and Amendment No 1 was
approved on 13 July 2015. Results will be presented at
scientific meetings and published.
Trial registration number: NCT02606227;
Pre-results.
INTRODUCTION
Smoking is a major public health issue
through its contribution to chronic diseases,
risk of disability and preventable mortality.
Smoking is also one of the most important
contributors to socioeconomic inequalities in
mortality. People from a low social back-
ground are more likely to smoke and ﬁnd it
harder to quit.1 2
The current status of tobacco control in
France has largely been criticised by two par-
liamentary reports3 4 and by a major report
of the Cour des comptes.5 Investment in inter-
ventions for reducing tobacco prevalence is
negligible compared with the social cost of
tobacco smoking, estimated to be €120
billion in 2010.6 In addition, interventions
are not sufﬁciently targeted to reach at-risk
populations and there is a lack of evaluation
of tobacco control interventions in terms of
both effectiveness and efﬁciency.
Among at-risk populations, pregnant
women are an important target for tobacco
control policies, since maternal smoking
during pregnancy (MSDP) is associated with
Strengths and limitations of this study
▪ Maternal smoking during pregnancy is asso-
ciated with adverse perinatal and postnatal health
outcomes and the most promising intervention
seems to be financial incentives to help pregnant
smokers quit.
▪ A randomised open-label study that will be run
in 16 maternity wards all over France, with
face-to-face monthly visits during pregnancy up
to delivery.
▪ Intervention group: progressively increasing
financial incentives (unit of vouchers €20)
rewarding abstinence and show-up (N to ran-
domise 199). Control group: €20 vouchers for
show-up (N to randomise 199).
▪ Main outcome measure: continuous and com-
plete abstinence from quit date to delivery.
▪ No long-term (over 6 months) follow-up of
infants.
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perinatal and postnatal adverse health outcomes7 8 such
as spontaneous abortion, premature birth and low birth
weight. Recent studies have also highlighted its long-
lasting effects on health outcomes of the offspring.9–15
MSDP may increase the risk of psychiatric comorbidity,
obesity, asthma and type 2 diabetes. It increases all-cause
mortality among offspring.7 Cohort studies have reported
that smoking in pregnancy is associated with increased
risk of childhood retinoblastoma,16 brain tumours,17 and
leukaemia and lymphoma.18 19
The last French perinatal survey20 reports that, in
2010, 30.5% of pregnant women (total sample 13 888)
were smokers before pregnancy, and ∼20% of the total
smoked at least 10 cigarettes per day. In 2010, 17% of
pregnant women smoked in the last trimester, which cor-
responds to 137 180 fetuses exposed in utero to active
smoking in the last trimester (802 224 births in 201021).
To the best of our knowledge, no national data exist
on: how many women stop smoking before pregnancy
and maintain full abstinence during fertilisation, the
ﬁrst and second trimester, and up to and during deliv-
ery; how many smoking women abstain partially during
pregnancy and at the time of delivery; and how many
relapse, and at what point, after giving birth. Most preg-
nant smokers reduce their consumption during preg-
nancy or smoke intermittently, and, if they quit, most of
them relapse after delivery,22–25 which is a main concern
because of postnatal second-hand smoke exposure of
the newborn/infant/child. The relapse rate varies
according to the country. As for other behavioural data
inﬂuenced by cultural, socioeconomic and genetic
factors, issues concerning smoking during and after
pregnancy are not automatically transposable to the
population of French pregnant smokers.
Nicotine replacement therapies (NRTs) are consid-
ered to be the cornerstone intervention to help smokers
quit. Their efﬁcacy has been demonstrated in various
populations of smokers.26 In pregnant smokers, NRTs
are still recommended by French health authorities,27
but, because of the lack of conclusive evidence on their
efﬁcacy for smoking cessation among pregnant women,
recommendations in the UK are more cautious,28 and
NRTs are not recommended in US guidelines.29
Previous trials,30–34 two meta-analyses35 36 and one sufﬁ-
ciently powered UK study37 concluded that NRTs are not
effective in helping pregnant smokers stop smoking. A
French multicentre, randomised, parallel group,
national study found that NRTs, even when adjusted for
nicotine uptake by smoking and when administered at
higher than usual doses of nicotine, do not result in
higher abstinence rates than placebo.38 The most recent
Cochrane meta-analysis concluded that, when all NRT
trials in pregnancy were taken into account, NRT use
can be associated with an increased rate of abstinence in
late pregnancy; however, when non-placebo-controlled
and potentially biased trials were excluded, placebo-
controlled randomised trials did not show efﬁcacy of
NRT use over placebo.39 Furthermore, there is no
evidence that NRTs in pregnancy have either beneﬁt or
adverse effect on birth outcomes.39
Contingency management interventions, such as pro-
viding tangible rewards for cigarette abstinence, are an
alternative to NRTs.
FINANCIAL INCENTIVES AND TOBACCO CONSUMPTION
The theoretical framework of the economics of
smoking40 41 provides several mechanisms to explain
tobacco consumption and potential instruments for
policy interventions. According to Grossman’s model of
health capital42 and Becker and Murphy’s model of
rational addiction,43 smoking is the result of a bargain
between the present satisfaction induced by tobacco con-
sumption and the direct costs of tobacco, delayed losses
induced by future tolerance, and potential losses in
health capital. If the demand for tobacco is elastic to
price variation, taxation is thus a natural incentive instru-
ment for reducing tobacco consumption by increasing
direct costs. This instrument has been shown to be efﬁ-
cient for reducing smoking initiation and for increasing
tobacco cessation among pregnant women as well as in
the general population of smokers.44 Despite tobacco
taxation, the proportion of smokers remains higher in
low-income than in high-income groups. While an
increased price through taxes diminishes tobacco con-
sumption among low-income individuals, it also raises
equity concerns, as spending on tobacco has more
weight in the budget of the low-income individual than
in that of the high-income individual. In addition, it is
difﬁcult to implement for a targeted subpopulation.45 46
The updated meta-analysis of studies of ﬁnancial
incentive interventions in smoking cessation in the
general population of smokers has shown that they
increase cessation rates while they are in place.47 The
meta-analysis of eight studies from the USA and UK
among pregnant smokers provided an OR of 3.60 (95%
CI 2.39 to 5.43) favouring ﬁnancial incentives over
control conditions.47 Although evidence is growing to
support the efﬁcacy of ﬁnancial incentives for smoking
cessation among pregnant smokers,48 to the best of our
knowledge, the data are from Anglo-Saxon countries
with different cultural and healthcare system back-
grounds from France.
On the other hand, a meta-analysis of various inter-
ventions (booklets, counselling, various psychotherapies,
NRTs, ﬁnancial incentives) to help pregnant smokers
quit has shown a very modest overall effect on abstin-
ence (relative risk (RR) 0.94; 95% CI 0.93 to 0.96).49
Among ﬁnancial incentive studies in pregnant
smokers, the study of Tappin et al50 has the highest
power. Pregnant smokers were randomised into a
control group (CG) and an intervention group (IG).
The CG (N=306) received routine care: setting of a quit
date, four-weekly phone calls, and 10 weeks of NRTs.
The IG received routine care and ﬁnancial incentives in
the form of shopping vouchers up to £400 (N=306).
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The main outcome measure was point prevalence abstin-
ence at gestational weeks 34–38 veriﬁed by saliva or
urinary cotinine. More pregnant smokers stopped
smoking in the IG than in the CG (22.5% vs 8.6%; abso-
lute risk difference 14% (95% CI 8.2% to 19.7%)).
There was no difference in birth weight of their off-
spring (3140 g, SD=600 vs 3120 g, SD=590).
The efﬁcacy of ﬁnancial incentives in helping preg-
nant smokers quit smoking has never been investigated
in the French context. Because of cultural, economic
and other individual and contextual differences, results
from other countries cannot be directly applied to
French pregnant smokers.
BEHAVIOURAL CHARACTERISTICS AND SMOKING IN
HEALTH ECONOMICS
According to the seminal framework of behavioural eco-
nomics of smoking,40 51 52 time preferences are deﬁned
by how individuals weight future events when a decision
involves delayed costs or beneﬁts as well as present ones.
The way individuals value time may affect present-day
health decisions.
Experimental and health economic studies have
reported that present-oriented individuals are more
likely to be smokers than forward-looking ones, since
present-oriented individuals overvalue the short-term sat-
isfaction derived from smoking compared with future
harmful consequences of tobacco smoking.41 On the
basis of subjective scales introduced in the 2008 French
National Health, Health Care and Insurance Survey
(ESPS), Jusot and Khlat53 found that being present-
oriented is associated with current smoking, even after
adjustment for education. Regarding quitting beha-
viours, Brown and Adams54 provided evidence from
Australian data that more-forward-looking individuals
are more likely to quit smoking. A study based on the
2004 wave of the ESPS survey by Grignon55 reported
that present-oriented individuals are more likely to quit
after more failed attempts and at an older age.
The way individuals value risky outcomes—referred to
as risk preference—may inﬂuence their likelihood of
smoking. Empirical studies have found a negative rela-
tionship between risk aversion and tobacco use.53 56
The health psychology literature explains smoking ces-
sation by various psychological determinants such as self-
efﬁcacy (ie, conﬁdence in one’s ability to abstain),
impulsivity, locus of control, and personality traits.
Self-efﬁcacy is a determinant of smoking cessation in the
sense that it is related to the likelihood of initiating and
maintaining an effort and being able to cope with
highly tempting situations (for a meta-analysis, see
Gwaltney et al57). Since self-efﬁcacy evolves during the
cessation process, it needs to be assessed continuously
during an intervention.
Choice impulsivity involves the preferential selection
of smaller–sooner rewards over larger–later rewards.58
Hence, smokers choose the immediate beneﬁts of
cigarettes over a healthier future life. This attitude is
usually associated with drug- and non-drug-related (eg,
pathological gambling) addictions. Several studies have
reported higher levels of impulsivity in smokers than in
non-smokers.59 Impulsivity usually also predicts a shorter
time of relapse because impulsive individuals are sup-
posed to be more sensitive to smoking cues.60
Locus of control is related to the extent to which indi-
viduals believe that they can control what happens to
them. The locus of control is to some degree internal
(the individual believes she controls her life) or external
(she believes that luck, fate or powerful others control
her life). Abstinence from smoking is associated with an
internally focused locus of control, such that individuals
who perceive themselves as controlling life events are
more likely to quit smoking.59
Personality traits from the ﬁve-factor model61 (open-
ness, conscientiousness, extraversion, agreeableness,
neuroticism) have been shown to be associated with
tobacco consumption. A meta-analysis62 has shown an
association between smoking and low conscientiousness,
low agreeableness and high neuroticism. Neuroticism is
related to smoking, especially among individuals with
low conscientiousness. Openness is signiﬁcantly asso-
ciated with motivation to quit and the number of quit
attempts of 24 hours during the past year.63
Financial incentives may be especially efﬁcient among
women with particular socioeconomic and behavioural
characteristics; they are expected to be particularly efﬁ-
cient among disadvantaged women who have a higher
marginal utility of consumption than more advantaged
ones. Similarly, providing immediate rewards for behav-
iour changes may help to reduce the effect of some
behavioural characteristics such as immediacy and time
preference. For instance, ﬁnancial incentives may be
more effective among present-oriented women who
overvalue short-term satisfaction of smoking compared
with future harmful consequences of tobacco smoking.
Immediate ﬁnancial incentives may neutralise the short-
term beneﬁt of smoking by increasing the short-term
beneﬁt of smoking cessation.
OBJECTIVES
The main objective of this study is to assess the efﬁcacy
of ﬁnancial incentives on smoking abstinence rate
among French pregnant smokers.
Secondary objectives include exploration of predictors
of response to ﬁnancial incentives such as socioeconomic
status, social background, smoking characteristics, locus
of control, impulsivity, self-efﬁcacy, personality traits, and
time and risk preferences, in order to determine proﬁles
of women who could be efﬁciently targeted by this kind
of intervention. Further objectives include: (a) a cost–
beneﬁt analysis based on the cost of pregnancy-related
and infant-disease-related costs due to MSDP with respect
to the cost and beneﬁt of using ﬁnancial incentives; (b)
an assessment of selection bias from agreeing to being
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part of the study or not by comparing women who gave
their consent to participate in the study and women who
did not.
METHODS AND ANALYSIS
Design
This will be a single-blind, randomised, two parallel
groups, national superiority trial run in 16 maternity
wards all over France. A total of 398 pregnant smokers
will be randomised (1:1 ratio) to the intervention
(N=199) and control (N=199) groups.
Participants
Consent
Participants’ written consent will be obtained by the
investigators. In order for birth outcome data to be col-
lected, participants will sign a statement to the effect
that they are not opposed to recording of birth outcome
data on the child to be born. These original documents
will be archived by the investigators in their respective
maternity wards.
Inclusion criteria
1. Pregnant women motivated to quit smoking (score
higher than 5 on a visual analogue scale ranging
from 0 (not at all motivated) to 10 (extremely
motivated)).
2. 18 years old or older.
3. Smoking at least ﬁve cigarettes per day or three
roll-your-own cigarettes per day.
4. Pregnancy of <18 weeks of amenorrhoea (WA).
5. Afﬁliated to National Health Insurance funds or to
another medical health insurance fund as required
by French law on biomedical research.
6. Having signed an informed written consent form
7. Agreeing to collection of birth characteristics of the
child to be born.
Exclusion criteria
1. Current treatment for a chronic psychiatric disorder
using neuroleptics, antidepressants or anxiolytics.
2. Use of tobacco products other than cigarettes.
3. Use of either bupropion or varenicline because their
use is contraindicated in pregnancy.
4. Because of the lack of knowledge on the health
beneﬁt–risk ratio of electronic cigarettes,64 electronic
cigarette users will be excluded.
NB Multiple pregnancies will not be an exclusion
criterion.
Setting and recruitment
Participants will be recruited, included and followed-up
in 16 maternity wards in France. The 16 centres are
expected to include 20–30 smoking pregnant women
every month. Assuming that each centre will randomise
15 women per year, we will be able to recruit 240
women per year.
Participants will be recruited by word of mouth, ﬂyers
and advertisements in pharmacies, local radio broad-
casts, local newspapers, general practitioner ofﬁces and
in the participating maternity wards. After a phone inter-
view for eligibility, pregnant smokers will be invited to
attend the closest maternity ward for a screening visit.
Investigators will be midwifes or physicians who rou-
tinely treat pregnant smokers. They should all have
obtained a smoking cessation specialist diploma and
should be familiar with smoking cessation issues among
pregnant smokers.
Randomisation
A computer-generated randomisation list in blocks of
four will be prepared by a statistician who is independ-
ent of the study. The randomisation list by centre will be
incorporated into the electronic case report form
(eCRF). A randomisation number will be allocated at
the ﬁrst visit after the participants’ characteristics have
been checked for inclusion/exclusion criteria and their
written informed consent obtained.
Interventions
During each visit, each woman will beneﬁt from a short
intervention for smoking cessation according to nation-
ally accepted guidelines whatever the study group they
belong to. It will include motivational counselling,
support and skill-training elements.65 66
All necessary care and interventions will be permitted
during the trial.
Chronology of the trial
A quit date will be set at randomisation. The quit date
should occur between randomisation and day 14.
Monthly face-to-face visits will be planned. The total
number of visits will depend on the date of delivery. For
example, if the quit date is at 12 WA and delivery at
40 WA, monthly visits will be carried out at WA 16, 20,
24, 28, 32 and 36 (six visits); if the quit date is at 16 WA
and delivery at 34 WA, four visits will be conducted (WA
20, 24, 28 and 32). The number of visits determines the
amount of monetary rewards earned for attending the
visits in both groups. The total duration of participation
in the study will be 12 months on average: ∼6 months
until giving birth and a follow-up phone call 6 months
after birth.
In cases of missed visits, participants will be called by
telephone at least twice, followed, in the case of non-
response, by regular mail to encourage them to attend
the next visit.
Incentives for abstinence
Monetary reward for abstinence will be given through
vouchers (Kadeos http://www.edenred.fr/besoin/avantages-
aux-salaries/produit/ticket-kadeos/) that can be redeemed
in many different shops and superstores; they cannot be
used to buy tobacco or alcohol products. The value of
each voucher will be €20. Participants in both control
4 Berlin N, et al. BMJ Open 2016;6:e011669. doi:10.1136/bmjopen-2016-011669
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and intervention groups will receive a €20 voucher as a
show-up fee for completing the visit.
Intervention group (IG)
Every participant can earn additional vouchers con-
ditional on her abstinence. For example, if the partici-
pant has abstained during ﬁve consecutive visits, she can
earn up to €380 of vouchers.
Figure 1 shows the payoff tree (in euros) that a partici-
pant can earn according to her group and abstinence,
under the assumption that she attends ﬁve visits.
In the IG, the payoffs are based on two principles: the
reward for abstinence today and the reward for continu-
ous (past) abstinence. Hence, the payoff increases with
the number of times a participant has been abstinent
but also with the number of successive abstinences.
If the participant is not abstinent (Ā), she gets a €20
voucher as a show-up fee. If she is abstinent (A), she
earns the show-up fee and an additional amount to
reward her abstinence. If she is abstinent at the ﬁrst post-
quit day visit she will be rewarded with an additional €40
of vouchers. This amount then increases by €20 progres-
sively if she remains abstinent for the next visits (€60,
€80 and €100). If a participant has been abstinent and
then non-abstinent, the next time she is abstinent, the
last abstinent payment will recur in order to reward her
abstinence and avoid penalty for the previous non-
abstinence. This feature also helps to reduce no-show,
especially if the participant has been abstinent. Table 1
refers to four different scenarios of ﬁnancial incentives
(in euros) according to the abstinence of the participant
over ﬁve visits.
If a participant does not show up for a visit but shows
up for the next visit, the no-show-up visit will be consid-
ered to be a non-abstinence visit, and therefore when
she shows up at the next visit, the ﬁnancial incentive will
be that of the last show-up visit.
A general expression allows us to determine the total
payoffs after the total number of visits, T, according to
each situation. Let YIGT be the total payoff after T visits in
the IG
YIGT ¼ 20þ ½40 NA2  IA2 þ 20 þ
XT
t¼3
ð20  IAt  ðNAt þ 1Þ þ 20Þ
for t ¼ f3; . . . ;Tg
The ﬁrst visit is the inclusion and randomisation visit
in both groups and everyone receives €20. NAt is the
number of successive times a pregnant woman has been
abstinent, measured at visit t. IAt is a dummy variable,
which is equal to 1 if the pregnant woman is abstinent at
visit t, and is equal to 0 otherwise.
Control group (CG)
Participants randomised to the CG will receive a €20
voucher at the end of each completed visit as a show-up
fee, but in contrast with the IG, abstinence will not be
rewarded. The total payoff will be a function of the total
number of visits the participant attended.
Figure 1 Payoff tree for both the intervention (contingency management) and control groups.
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Table 1 Four examples of financial incentives in euros according to abstinence (A)/non-abstinence (Ā) of pregnant women at study visits (V)
Scenario for 5 visits R=V1 (€) V2 V3 V4 V5 Total gain
1. RAAAA 20 A
IA2 ¼ 1; NA2 ¼ 1
40 1 1þ 20 ¼ 60
A
IA3 ¼ 1; NA3 ¼ 2
20ð2þ 1Þ1þ 20 ¼ 80
A
IA4 ¼ 1; NA4 ¼ 3
ð20ð3þ 1Þ1þ 20Þ ¼ 100
A
IA5 ¼ 1; NA5 ¼ 4
ð20ð4þ 1Þ1þ 20Þ ¼ 120
20+360
2. RAAĀĀ 20 A
IA2 ¼ 1; NA2 ¼ 1
40 1 1þ 20 ¼ 60
A
IA3 ¼ 1; NA3 ¼ 2
20ð2þ 1Þ1þ 20 ¼ 80
Ā
IA4 ¼ 0; NA4 ¼ 2
ð20ð2þ 1Þ0þ 20Þ ¼ 20
Ā
IA5 ¼ 0; NA5 ¼ 2
ð20ð2þ 1Þ0þ 20Þ ¼ 20
20+180
3. RAĀAĀ 20 A
IA2 ¼ 1; NA2 ¼ 1
40 1 1þ 20 ¼ 60
Ā
IA3 ¼ 0; NA3 ¼ 1
ð20ð1þ 1Þ0þ 20Þ ¼ 20
A
IA4 ¼ 1; NA4 ¼ 1
20ð1þ 1Þ1þ 20 ¼ 40
Ā
IA5 ¼ 0; NA5 ¼ 1
ð20ð1þ 1Þ0þ 20Þ ¼ 20
20+160
4. RĀAAĀ 20 Ā
IA2 ¼ 0; NA2 ¼ 1
40 1 0þ 20 ¼ 20
A
IA3 ¼ 1; NA3 ¼ 1
ð20ð1þ 1Þ1þ 20Þ ¼ 40
A
IA4 ¼ 1; NA4 ¼ 2
20ð2þ 1Þ1þ 20 ¼ 60
Ā
IA5 ¼ 0; NA5 ¼ 2
ð20ð2þ 1Þ0þ 20Þ ¼ 20
20+180
YIGT ¼ 20þ ½40NA2 IA2 þ 20 þ
PT
t¼3
ð20IAt ðNAt þ 1Þ þ 20Þ for t ¼ f3; . . . ;Tg:
The first scenario RAAA refers to a participant who was randomised to the intervention group (IG) during the first visit and was abstinent in the following four visits. Hence, during the second
visit (t=2), she would get a €20 voucher for showing up plus a €40 voucher for being abstinent (because she is abstinent IA2 ¼ 1 and because it’s the first time since randomisation she’s being
checked for being abstinent, then NA2 ¼ 1). At the last visit (t=5), showing up and being abstinent ðIA5 ¼ 1Þ for the fourth time (NA5 ¼ 4) yields a voucher of 20+20(4+1)1=€120.
The second scenario RAAĀĀ refers to a participant who was randomised to the IG during the first visit and abstinent at the 2nd and 3rd visits, and non-abstinent at the 4th and 5th visits. Hence,
for the second visit, the abstinent participant would receive the €20 voucher show-up fee plus the €40 voucher for being abstinent (IA2 ¼ 1 and NA2 ¼ 1). At the third visit, by showing up she
would get the €20 voucher, and by being abstinent (IA3 ¼ 1) for the second consecutive time (NA3 ¼ 2), she would receive an additional €20(2+1)1 = €60 voucher, etc.
If one looks at scenario 4, the participant is being randomised to the IG at the first visit, then is not abstinent at the 2nd visit, abstinent at the 3rd and 4th visits, and not abstinent at the 5th visit.
Hence, during visit 4, for example, she would receive the €20 voucher for showing up, and, by being abstinent (IA4 ¼ 1) for the second consecutive time (NA4 ¼ 2), she would get a €20×(2+1)×1=
€60 voucher. However, as in the 5th visit she is not abstinent, she then gets the €20 show-up voucher.
R, randomisation visit, V1.
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Hence, the total payoff for participants in the CG is
YGCT ¼ 20  t; for t ¼ f1; . . . ;Tg
Outcomes
Main outcome measure
The main outcome measure will be the continuous
smoking abstinence from the predeﬁned quit date until
the last predelivery visit.
Previous studies were mainly interested in whether
smoking reduction is associated with reduced birth
weight. Two earlier studies67 68 reported that smoking
reduction among pregnant smokers had no impact on
birth weight. Two subsequent studies69 70 have shown
that reduced cigarette consumption decreased but did
not nullify smoking-related loss in birth weight. At the
public health level, even a small reduction in a popula-
tion’s birth weight may have long-lasting consequences
for the offspring. Continuous abstinence since quit date
has a higher likelihood of suppressing smoking-related
loss in birth weight than smoking reduction. For this
reason, continuous abstinence since quit date has been
chosen as the main outcome measure.
Secondary outcome measures
For mothers:
▸ Point prevalence abstinence at visits deﬁned as self-
reported no smoking in the last 7 days and expired
air carbon monoxide ≤8 ppm.
▸ Time (days) to ﬁrst cigarette after quit date (lapse
(a few puffs) or relapse).
▸ Total number of cigarettes smoked per day.
▸ Craving to smoke and withdrawal symptom scores.
For newborns:
▸ Birth weight and other birth characteristics such as
head circumference, length, Apgar score at 5 min.
▸ Gestational age at birth.
▸ Assessment of intrauterine growth restriction calcu-
lated by AUDIPOG (http://www.augipog.net), a
national network of intrauterine growth data.
Negative health outcomes during pregnancy (mater-
nal and fetal) and at birth will be recorded from clinical
charts.
Power calculation
A previous study38 that compared nicotine patches with
placebo patches in pregnant smokers has shown a con-
tinuous abstinence rate of 5.5% in the nicotine group vs
5.1% in the placebo group. Some 53% of women in the
nicotine group did not show up for every visit compared
with 62% in the placebo group. In Tappin et al,50 more
smokers who were provided with ﬁnancial incentives
(22.5%) had stopped smoking than in the non-
incentivised group (8.6%). It is noteworthy that, in this
study, the main outcome measure was point prevalence
abstinence at 34–38 WA and not continuous abstinence
as in the present study.
The power calculation is based on the main outcome
measure. We assume that the abstinence rate among
pregnant women will be 10% in the CG and either 25%
or 20% in the IG, as presented in table 2. We hypothe-
sise a 10% continuous abstinence rate, double that previ-
ously observed38 in the CG because of the ﬁnancial
reward of showing-up, which may in itself increase the
abstinence rate by increasing show-ups. According to
table 2, assuming a 20% abstinence rate in the IG, a con-
servative approach, with an α=0.05 and 1−β=0.80, we
would need to randomise 199 women to each group.
In Tappin et al,50 the lost-to-follow-up rate is 14% and
15% at the primary end point of gestational weeks
34–38. Because of the high frequency (monthly) of
face-to-face visits and because show-ups are rewarded
with €20, we assume an overall dropout rate of 5%,
implying that we would need to randomise 420 pregnant
smokers. We assume that approximately 40 women by
group will not show up for the ﬁrst visit, and as a conse-
quence, we expect to recruit between 460 and 480
women who signed the informed consent forms to
ﬁnally randomise 420.
Independent variables
1st visit:
▸ Demographic, socioeconomic, obstetric and smoking
characteristics
▸ Age
▸ Household income
▸ Self-reported ethnic origin
▸ Medical, psychiatric history
▸ Obstetric history: number of previous pregnancies,
abortions, miscarriages, deliveries, premature delivery,
number of children
▸ Weeks of amenorrhoea
▸ Smoking history and characteristics
– Age smoked ﬁrst cigarette
– Partner’s smoking
– Second-hand smoke exposure
Table 2 Power calculation for the number of participants
needed to demonstrate a statistically significant difference
in the main outcome measure with a randomisation
ratio of 1:1
α 1−β
N for control
group
N for intervention
group
1. Two-sided hypothesis: abstinence rate =10%
in the control group and =25% in the intervention group
0.05 0.90 133 133
0.05 0.85 114 114
0.05 0.80 100 100
2. Two-sided hypothesis: abstinence rate =10%
in the control group and =20% in the intervention group
0.05 0.90 266 266
0.05 0.85 228 228
0.05 0.80 199 199
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– Number of cigarettes smoked during the last 7 days
– Fagerström Test for Cigarette Dependence71
– Craving for tobacco using French Tobacco Craving
Questionnaire (FTCQ-12)72
– Withdrawal Symptoms Questionnaire73 74
– Expired air CO concentration (Smokerlyzer;
Bedfont, Maidstone, Kent, UK)
– Cannabis consumption in the last 30 days
▸ Alcohol consumption in the last 30 days
▸ Evaluation of alcohol dependence (CAGE
questionnaire)75
▸ Current use of psychotropic medications
▸ Weight (kg) and height (cm)
▸ Sitting systolic and diastolic blood pressure
Behavioural measures:
▸ Time preferences: the subjective scale from ESPS and
the scale for consideration of future consequences
(validated measure in French)53
▸ Risk preferences: a subjective scale tested and vali-
dated in the ESPS survey which measures the willing-
ness to take risks. We will also use a measure developed
by Dohmen et al,76 which measures risk aversion in
domain-speciﬁc risks (ﬁnancial, health, social)
▸ Impulsivity: Barratt Impulsivity Scale77- validated French
version78
▸ Locus of control: Fetal Health Locus of Control
(FHLC) created and validated by Labs and Wurtele.79
To guarantee validity, this measure will be adminis-
tered twice: once at inclusion (visit 1) and once
halfway through the study (visit 3)
▸ Big Five personality test:60 78 a short (<1 min to com-
plete) assessment of personality traits, such as extraver-
sion, conscientiousness, agreeableness, neuroticism
and openness to experience
A urine sample will be collected to quantify con-
centration of anabasine, anatabine and cotinine. The jus-
tiﬁcation for this is as follows. Nicotine accounts for ∼85–
95% of the alkaloid content of tobacco, while anabasine
and anatabine are among the most abundant minor
tobacco alkaloids.80 81 Owing to the relatively short elim-
ination half-life of nicotine (about 2 hours), investigating
nicotine metabolites that exhibit a longer half-life is a
prerequisite to providing relevant information on
tobacco consumption. Cotinine is the main metabolite of
nicotine whose mean elimination half-life can be shorter
during pregnancy. Tobacco use increases the urinary
concentration of all three compounds. Complete abstin-
ence from tobacco or no use of NRTs is associated with
<3 ng/mL urinary anabasine and <10 ng/mL urinary
anatabine. The measure of non-nicotinic alkaloids allows
us to distinguish no tobacco use from NRT use, which is
associated with urinary cotinine concentration >10 ng/
mL. A pregnant woman will therefore be considered not
to be smoking and not receiving NRT if she reports no
smoking and her expired air CO is ≤8 ppm, her urinary
anabasine is ≤3 ng/mL and her urinary cotinine is
≤10 ng/mL. Because anatabine’s cut-off values are less
well established, its determination will not be used in the
primary assessment of abstinence. Quantiﬁcation of the
three compounds in urine samples will be performed by
ultra-high performance liquid chromatography coupled
with tandem mass spectrometry after a dedicated sample
preparation procedure.82 83
Follow-up visits: 2nd to last visit (visit 5 or 6):
▸ Self-reported smoking status (abstinent or not) and
expired air CO
▸ Number of cigarettes smoked in the last 7 days
▸ Use of NRT: type and daily dose
▸ Use (or not) of an electronic cigarette
▸ FTCQ-12
▸ Withdrawal Symptoms Questionnaire
▸ Cannabis consumption in the last 30 days
▸ Alcohol consumption since last visit: Yes/No
▸ Weight
▸ Sitting systolic and diastolic blood pressure
▸ Any negative health event related or not to the preg-
nancy. At visit 3, participants will be asked to com-
plete a short questionnaire including the FHLC
▸ Urine sample: as mentioned above, one urine sample
will be collected during the inclusion visit (visit 1). A
second sample will be randomly collected at visit 2, 3
or 4 according to a random list included in the eCRF.
The post-quit day urine sample will allow us to
control for self-reported abstinence
Postpartum follow-up: 6 months:
Participants will be contacted 6 months after delivery
for a phone interview. This follow-up survey will record
data about the child’s evolution, about the smoking
status of the mother and the partner, breastfeeding, sat-
isfaction about the intervention, marital and employ-
ment status, and an assessment of stress since delivery.84
Data management
Data will be entered into the eCRF using CleanWEB soft-
ware with range checks for data values. Source documents
will be kept by the investigation centres (maternity
wards). Data recorded in the eCRF will be double-
checked by a research monitoring assistant. This research
complies with the law of 6 January 1978 article 54 and
was declared to the Commission nationale de l’informa-
tique et des libertés (CNIL) (https://www.formulaires.
modernisation.gouv.fr/gf/cerfa_13810.do). All data will
be recorded anonymously using the centre number
(three digits), randomisation number (four digits) and
the ﬁrst letter of the participants’ name and surname.
DATA ANALYSIS
Outcomes will be analysed on an intention-to-treat
(ITT) basis. The ITT population is deﬁned as all rando-
mised smoking pregnant women. The completer popu-
lation will be deﬁned as the population that completed
all visits.
Participants who do not show up at a visit will be con-
sidered to be smoking (non-abstinent) for this missed
visit.
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Smoking relapse or multiple missed visits will not be a
criterion for dropout. Participation in the study ends if
pregnancy ends (delivery or any other reasons such as mis-
carriage). Data of a participant who withdraws her consent
to participate will not be included in the ITT database.
Main analysis
The main outcome measure for the mother will be com-
plete continuous abstinence since the quit date, which will
be deﬁned as abstinence at each visit (self-reported abstin-
ence during the last 7 days and expired air CO ≤8 ppm)
from randomisation to delivery (ie, last study visit before
delivery). Abstinence rates will be compared between the
intervention and control groups using Fisher’s exact test.
Secondary analyses
Relapse to smoking will be described by Kaplan–Meier
curves and compared with the log-rank test.
Multivariate analyses will be performed to evaluate the
determinants of continuous abstinence since quit date
to delivery. Control variables for the intervention effect
will be the sociodemographic, tobacco-related, psycho-
logical and behavioural characteristics, duration and
total dose of NRTs, and centres.
The analysis will include interacting subgroup
characteristics such as, for instance, how this probability
varies for low and highly educated women who are
strongly present-oriented.
The ﬁrst questionnaire that will be ﬁlled in by women
taking part in the study and those who do not will
provide an insight into the selection bias to participate in
the study.
No interim analysis is planned. Unlike medications,
ﬁnancial incentives—the intervention assessed by this
trial—cannot lead to premature stopping of the study
because of adverse health outcomes.
Sensitivity analyses
1. Differences between intervention and control groups
for both main and secondary outcomes will also be
analysed according to biochemical veriﬁcation of
abstinence based on negative anabasine, self-report
of no smoking, and expired air CO ≤8 ppm.
2. A second sensitivity analysis of efﬁcacy will be run in
which participants with missing visit(s) will be
imputed as smokers versus imputing non-smoking if
a participant misses a visit between two visits for
which she was abstinent.
Ancillary analysis
The diagnostic validity of urinary anabasine and anata-
bine for abstinence will be assessed (sensitivity, speciﬁ-
city, negative and positive prognostic value).
Analysis of adverse pregnancy outcomes
It cannot be assumed that ﬁnancial incentive interven-
tions contribute to adverse pregnancy and/or birth out-
comes. However, it can be hypothesised that an increased
abstinence rate in the ﬁnancial incentive group may
reduce adverse pregnancy and birth outcomes.
Adverse pregnancy outcomes such as premature birth,
miscarriage, abortion (medical or voluntary), stillbirth,
caesarean section, haemorrhage at delivery, newborn’s
transfer to neonatal intensive care unit will be recorded
and tabulated by group in a descriptive manner. Because
the intervention cannot lead to adverse health effects, no
safety monitoring committee will be implemented.
DISCUSSION
In this study, we will investigate the effect of ﬁnancial
incentives on smoking cessation and abstinence during
pregnancy with the hypothesis that ﬁnancial rewarding
of abstinence (IG) compared with the lack of ﬁnancial
incentive (CG) will increase the abstinence rate.
Face-to-face monthly visits are planned up to delivery.
Showing up to visits will be rewarded with €20 with the
hope that it will increase attendance.
One previous study has shown improved abstinence
rate as the result of ﬁnancial incentives50 among British
pregnant smokers. However, major cultural differences
and the potentially higher acceptability of ﬁnancial
incentives for rewarding abstinence in pregnant smokers
in France than in the UK means that such an interven-
tion needs to be tested in this target population.
An increased continuous rate of abstinence resulting
from ﬁnancial incentives may improve pregnancy and
birth outcomes, in particular birth weight, much more
than occasional point prevalence abstinence because it
may suppress or at least reduce tobacco-associated intra-
uterine growth restriction. Compared with intermittent,
point prevalence abstinence, continuous complete
abstinence may have a greater public health impact.
Identiﬁcation of socioeconomic and behavioural predic-
tors of outcome will help to characterise speciﬁc sub-
groups that respond better to ﬁnancial incentives.
Cost–benefit analysis
A cost–beneﬁt analysis will be undertaken after the com-
pletion of the trial. It will use costs related to pregnancy
when the mother smoked during pregnancy compared
with the costs of implementing ﬁnancial incentives,85
but it will also include costs related to postnatal infant
health disorders (such as wheezing, asthma, psychiatric
and metabolic disorders) whose risk factors include
MSDP.
Trial management
The Coordinating Centre at the Hôpital Pitié-Salpêtrière,
Université P. and M. Curie Faculté de medicine,
Département de pharmacologie and Unité de recherche
clinique takes responsibility for all aspects of the study:
ethical, regulatory, study conduction, data-management
and publication strategy. It will supervise and coordinate
the realisation of the trial and be in continuous contact
with the study’s centres (maternity wards).
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Coordinating Centre Members: Chair, Ivan Berlin; data
management, Leontine Goldzahl; medicoeconomics,
Noémi Berlin and Florence Jusot; monitoring and adminis-
tration, Jessica Palmyre, France Boyaud and Shoreh Azimi.
No drug safety monitoring committee will be
established.
ETHICS AND DISSEMINATION
As dictated by French law on biomedical research, all
participants can withdraw from the study at any time
and without any justiﬁcation. The research protocol was
approved by the ethics committee (Comité de Protection
des Personnes, CPP) of the Pitié-Salpêtrière Hospital on
15 May 2015. Amendment No 1 was approved on 13 July
2015. A consent form in French is available upon request.
Results will be presented at scientiﬁc meetings. The
authors commit themselves to publish all results of this
study in medical, health economic or other scientiﬁc
journals. The data will be the property of the sponsor,
the Assistance public-Hôpitaux de Paris (APHP). The
disposition of data sharing and data deposition will be
deﬁned by the sponsor.
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